| Literature DB >> 28810554 |
Su-Jin Kang1,2, Beom-Rak Choi3, Seung-Hee Kim3, Hae-Yeon Yi3, Hye-Rim Park3, Chang-Hyun Song1,4, Sae-Kwang Ku1,4, Young-Joon Lee1,2.
Abstract
The present study investigated the anti-aging effects of pomegranate juice concentrated powder (PCP) in hairless mice following 15 weeks of UVB irradiation (three times a week; 0.18 J/cm2). Skin moisturizing effects were evaluated through skin water, collagen type I and hyaluronan contents, as well as collagen type I and hyaluronan synthesis-related transcript levels. Wrinkle formation and edema scores (skin weights) were also assessed, along with skin matrix metalloproteinase (MMP)-1, MMP-9 and MMP-13 transcript levels. To determine the anti-inflammatory effects of PCP, myeloperoxidase (MPO) activity, interleukin (IL)-1β and IL-10 contents were observed. Caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) were used as an apoptotic index in epidermal keratinocytes. To determine the anti-oxidative effects of PCP, nitrotyrosine and 4-hydroxynonenal immunoreactive cells were detected and glutathione (GSH) content, malondialdehyde levels, superoxide anion production, Nox2, and GSH reductase mRNA expression were all measured. The results indicated that skin wrinkles induced by photoaging were significantly reduced by PCP, whereas skin water contents, collagen type I and hyaluronan contents all increased. Furthermore, IL-1β levels in the PCP-treated groups were lower than those in the UVB-exposed control group. UVB-induced GSH depletion was also inhibited by PCP. Taken together, the results of the current study suggest that PCP has favorable protective effects against UVB-induced photoaging through anti-apoptotic effects, MMP activity inhibition and ECM (COL1 and hyaluronan) synthesis-related moisturizing, anti-inflammatory and anti-oxidative effects.Entities:
Keywords: anti-inflammatory effect; antioxidant effect; apoptosis; dried pomegranate juice concentrated powder; photoaging; skin moisturizing effect; ultraviolet B
Year: 2017 PMID: 28810554 PMCID: PMC5525583 DOI: 10.3892/etm.2017.4626
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Primer sequences for reverse transcription-quantitative polymerase chain reaction.
| Target | Primer sequence (5′-3′) |
|---|---|
| Has 1 | |
| Forward | GCATGGGCTATGCTACCAAGTAT |
| Reverse | AGGAGGGCGTCTCCGAGTA |
| Has 2 | |
| Forward | GACCCTATGGTTGGAGGTGTTG |
| Reverse | ACGCTGCTGAGGAAGGAGATC |
| Has 3 | |
| Forward | AGACCGAGCTAGCCTTCCTAGT |
| Reverse | TAATGGCCAGATACAGCATGAG |
| COL1A1 | |
| Forward | GCGGTAACGATGGTGCTGTT |
| Reverse | CTTCACCCTTAGCACCAAC |
| COL1A2 | |
| Forward | ATTGTCGCCAGTGAG |
| Reverse | CTGGTCCTGCTGGT |
| MMP-1 | |
| Forward | AAGGTTAGCTTACTGTCACACGCTT |
| Reverse | CGACTCTAGAAACACAAGAGCAAGA |
| MMP-9 | |
| Forward | CCCGGACCAAGGATACAG |
| Reverse | GGCTTTCTCTCGGTACTG |
| MMP-13 | |
| Forward | CATCCATCCCGTGACCTTAT |
| Reverse | GCATGACTCTCACAATGCGA |
| GSH reductase | |
| Forward | TGCGTGAATGTTGGATGTGTACCC |
| Reverse | CCGGCATTCTCCAGTTCCTCG |
| Nox2 | |
| Forward | AGCTATGAGGTGGTGATGTTAGTGG |
| Reverse | CACAATATTTGTACCAGACAGACTTGAG |
| β-actin | |
| Forward | AGCTGCGTTTTACACCCTTT |
| Reverse | AAGCCATGCCAATGTTGTCT |
Has, hyaluronic acid synthase; COL1A, collagen, type I α; MMP, matrix metalloproteinase; GSH reductase, glutathione reductase; Nox2, gp91phox subunit of the phagocyte NADPH oxidase.
Primary antiserum and detection kits used in the present study.
| Product | Catalog no. | Supplier | Dilution |
|---|---|---|---|
| Primary antiserums | |||
| Anti-cleaved caspase-3 (Asp175) polyclonal antibody | 9661 | Cell Signaling Technology Inc., Danvers, MA, USA | 1:400 |
| Anti-cleaved poly(ADP-ribose) polymerase (Asp214) specific antibody | 9545 | Cell Signaling Technology Inc., Danvers, MA, USA | 1:100 |
| Anti-4-Hydroxynonenal polyclonal antibody | Ab46545 | Abcam, Cambridge, UK | 1:100 |
| Anti-Nitrotyrosine polyclonal antibody | 06–284 | EMD Millipore, Billerica, MA, USA | 1:200 |
| Anti-Matrix metalloprotease-9 mouse antibody | Ab38898 | Abcam, Cambridge, UK | 1:100 |
| Detection kits | |||
| Vectastain Elite ABC kit | PK-6200 | Vector Laboratories, Inc., Burlingame, CA, USA | 1:50 |
| Peroxidase substrate kit | SK-4100 | Vector Laboratories, Inc., Burlingame, CA, USA | 1:50 |
All antiserums were diluted with 0.01 M phosphate buffered saline.
Figure 1.Representative gross images of dorsal back skin (top panel) and replicas (bottom panel) taken from unexposed intact or UVB-exposed hairless mice. (A) Unexposed normal vehicle control hairless mice treated with distilled water; (B) UVB-exposed vehicle control hairless mice administered distilled water; (C) UVB-exposed hairless mice administered 2 ml/kg PCS; (D) UVB-exposed hairless mice administered 100 mg/kg PCP; (E) UVB-exposed hairless mice administered 200 mg/kg PCP; (F) UVB-exposed hairless mice administered 400 mg/kg PCP. Scale bars=10 mm; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Figure 2.Changes in the mean length and depth of wrinkles in skin replicas following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice. Significant increases in (A) mean length and (B) average depth of skin wrinkles were detected in the skin replicas of UVB control mice compared with the intact controls. Values are expressed as the mean ± standard deviation (n=8). P-values were determined by the least significant difference test. *P<0.05 and **P<0.01 vs. intact control; †P<0.01 vs. UVB control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Figure 3.Changes in skin edema scores. The graph presents the 6-mm diameter skin weights following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice. Values are expressed the mean ± standard deviation (n=8). P-values were determined by the least significant difference test. *P<0.05 and **P<0.01 vs. intact control; †P<0.01 vs. UVB control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Changes in skin water, COL1 and hyaluronan contents following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Groups | Skin water contents (%/6 mm-diameter skin) | Skin COL1 contents (%) | Skin hyaluronan contents (ng/ml) |
|---|---|---|---|
| Controls | |||
| Intact | 37.14±3.47 | 98.61±14.32 | 2.51±0.54 |
| UVB | 17.96±3.05[ | 44.41±10.53[ | 1.01±0.18[ |
| Reference | |||
| PCS 2 ml/kg | 26.54±2.80[ | 58.16±5.50[ | 1.35±0.20[ |
| PCP | |||
| 100 mg/kg | 26.74±2.42[ | 58.82±7.44[ | 1.42±0.14[ |
| 200 mg/kg | 29.66±3.31[ | 65.34±8.57[ | 1.68±0.21[ |
| 400 mg/kg | 32.18±2.86[ | 73.83±6.30[ | 1.82±0.21[ |
Values are expressed as mean ± standard deviation (n=8).
P<0.01 vs. intact control
P<0.01 vs. UVB control. UVB, ultraviolet B; PCS, pomegranate juice concentrated solution; PCP, dried pomegranate juice concentrated powder; COL1, collagen type I.
Changes in skin MPO activity, IL-1β and IL-10 levels following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Groups | MPO (Numbers of neutrophils ×105/mg protein) | IL-1β (pg/100 mg protein) | IL-10 (pg/100 mg protein) |
|---|---|---|---|
| Controls | |||
| Intact | 1.41±0.42 | 20.43±3.28 | 318.88±72.13 |
| UVB | 11.14±2.38[ | 62.10±11.63[ | 146.63±30.91[ |
| Reference | |||
| PCS 2 ml/kg | 7.77±1.72[ | 42.63±5.49[ | 192.63±8.85[ |
| PCP | |||
| 100 mg/kg | 7.38±1.60[ | 41.53±11.02[ | 211.00±44.98[ |
| 200 mg/kg | 4.84±1.40[ | 37.31±12.16[ | 229.63±33.41[ |
| 400 mg/kg | 4.41±1.19[ | 31.21±10.85[ | 238.00±24.37[ |
Values are expressed as mean ± standard deviation (n=8).
P<0.01 vs. intact control
P<0.01 vs. UVB control
P<0.05 vs. UVB control
P<0.05 vs. intact control. IL, interleukin; MPO, myeloperoxidase; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Changes in the skin antioxidant defense systems following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Groups | GSH (mg/mg protein) | MDA (ng/mg protein) | Superoxide anion production (OD at 600 nm) |
|---|---|---|---|
| Controls | |||
| Intact | 0.46±0.17 | 25.58±10.14 | 0.36±0.12 |
| UVB | 0.11±0.03[ | 132.59±22.30[ | 1.04±0.20[ |
| Reference | |||
| PCS 2 ml/kg | 0.17±0.04[ | 84.49±18.89[ | 0.74±0.09[ |
| PCP | |||
| 100 mg/kg | 0.18±0.03[ | 70.08±10.33[ | 0.73±0.11[ |
| 200 mg/kg | 0.24±0.03[ | 59.63±8.53[ | 0.63±0.17[ |
| 400 mg/kg | 0.27±0.04[ | 48.10±10.85[ | 0.52±0.12[ |
Values are expressed as mean ± standard deviation (n=8).
P<0.01 vs. intact control
P<0.01 vs. UVB control
P<0.05 vs. intact control. MDA, malondialdehyde; GSH, glutathione; OD, optical density; UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Changes in skin mRNA expression following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Control | PCP | |||||
|---|---|---|---|---|---|---|
| Groups | Intact | UVB | Reference PCS 2 ml/kg | 100 mg/kg | 200 mg/kg | 400 mg/kg |
| Has 1 | 1.02±0.11 | 1.03±0.21 | 1.85±0.32[ | 2.41±0.37[ | 2.91±0.55[ | 3.89±1.17[ |
| Has 2 | 1.05±0.11 | 0.99±0.11 | 1.59±0.22[ | 1.79±0.27[ | 2.25±0.41[ | 4.10±1.23[ |
| Has 3 | 1.05±0.15 | 0.98±0.11 | 1.58±0.41[ | 1.71±0.34[ | 3.05±0.93[ | 3.67±1.70[ |
| COL1A1 | 1.00±0.12 | 0.97±0.20 | 2.60±0.41[ | 3.03±0.56[ | 3.75±0.99[ | 4.76±1.62[ |
| COL1A2 | 1.01±0.14 | 1.00±0.09 | 2.62±0.45[ | 3.01±0.54[ | 3.74±0.98[ | 4.73±1.85[ |
| MMP-1 | 1.01±0.08 | 2.05±0.21[ | 1.71±0.24[ | 1.63±0.19[ | 1.51±0.24[ | 1.33±0.26[ |
| MMP-9 | 1.02±0.07 | 1.91±0.21[ | 1.65±0.15[ | 1.55±0.18[ | 1.37±0.16[ | 1.24±0.11[ |
| MMP-13 | 0.95±0.08 | 2.57±0.47[ | 1.95±0.21[ | 1.86±0.22[ | 1.65±0.19[ | 1.40±0.11[ |
| GSH reductase | 1.18±0.34 | 0.57±0.14[ | 0.76±0.11[ | 0.84±0.12[ | 1.07±0.17[ | 1.21±0.18[ |
| Nox2 | 1.05±0.14 | 2.02±0.27[ | 1.52±0.19[ | 1.49±0.16[ | 1.41±0.14[ | 1.27±0.17[ |
Values are expressed as mean ± standard deviation (n=8), relative expression/β-actin mRNA.
P<0.01 vs. intact control
P<0.01 vs. UVB control
P<0.05 vs. UVB control
P<0.05 vs. intact control. UVB, ultraviolet B; COL1, collagen, type I; COL1A1, COL1 α 1; COL1A2, COL1, α 2; GSH, glutathione; Has, hyaluronic acid synthase; MMP, matrix metalloproteinase; Nox2, gp91phox subunit of the phagocyte NADPH oxidase; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Figure 4.Representative histological images of dorsal back skin tissues taken from unexposed intact or UVB exposed hairless mice. (A) Intact vehicle control; (B) UVB control; (C) UVB-exposed mice treated with 2 ml/kg PCS; (D) UVB-exposed mice treated with 100 mg/kg PCP; (E) UVB-exposed mice treated with 200 mg/kg PCP; (F) UVB-exposed mice treated with 400 mg/kg PCP. Arrows indicate microfolds formed. Scale bars=100 µm. UVB, ultraviolet B; MT, Masson's trichrome; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
General histomorphometrical analysis of skin following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Groups | No. of microfolds (folds/mm of epidermis) | Mean epithelial thickness (µm/epidermis) | Mean inflammatory cells (cells/mm2 of dermis) | Collagen fiber occupied regions (%/mm2 of dermis) |
|---|---|---|---|---|
| Controls | ||||
| Intact | 8.75±4.40 | 19.11±2.12 | 10.25±4.20 | 42.52±4.59 |
| UVB | 70.88±14.38[ | 47.39±8.29[ | 241.25±39.15[ | 76.51±7.06[ |
| Reference | ||||
| PCS 2 ml/kg | 46.00±11.93[ | 30.60±5.51[ | 186.93±24.73[ | 64.92±5.26[ |
| PCP | ||||
| 100 mg/kg | 40.75±10.05[ | 29.00±4.44[ | 171.50±28.35[ | 60.98±10.95[ |
| 200 mg/kg | 33.25±10.07[ | 25.72±5.61[ | 149.38±32.95[ | 58.64±4.25[ |
| 400 mg/kg | 23.88±11.24[ | 23.86±4.54[ | 113.88±26.82[ | 54.71±4.28[ |
Values are expressed as mean ± standard deviation (n=8).
P<0.01 vs. intact control
P<0.01 vs. UVB control
P<0.05 vs. UVB control
P<0.05 vs. intact control. UVB, ultraviolet B; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Figure 5.Representative immunohistochemistrical images of dorsal back skin tissues, taken from unexposed intact or UVB-exposed hairless mice. (A) Intact vehicle control; (B) UVB control; (C) UVB-exposed mice treated with 2 ml/kg PCS mice; (D) UVB-exposed mice treated with 100 mg/kg PCP; (E) UVB-exposed mice treated with 200 mg/kg PCP; (F) UVB-exposed mice treated with 400 mg/kg PCP. All avidin-biotin complex immunostaining. Scale bars=50 µm. UVB, ultraviolet B; 4-HNE, 4-hydroxynonenal; PARP, cleaved poly(ADP-ribose) polymerase; MMP-9, matrix metalloproteinase 9; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.
Immuno-histomorphometrical analysis of skin following 15 weeks continuous oral administration of PCP or PCS in UVB-exposed mice.
| Epidermal immunoreactive cells (cells/100 epithelial cells) | |||||
|---|---|---|---|---|---|
| Groups | NT | 4-HNE | Caspase-3 | PARP | Dermis MMP-9 immunoreactivity (%) |
| Controls | |||||
| Intact | 11.38±5.83 | 12.50±4.87 | 16.13±6.64 | 15.38±7.33 | 28.88±10.82 |
| UVB | 82.50±11.17[ | 71.75±10.43[ | 83.00±10.20[ | 80.75±10.98[ | 75.88±13.27[ |
| Reference | |||||
| PCS 2 ml/kg | 52.00±11.12[ | 53.38±11.86[ | 58.25±10.95[ | 52.63±11.29[ | 56.63±11.48[ |
| PCP | |||||
| 100 mg/kg | 47.50±8.99[ | 42.13±10.36[ | 41.25±10.96[ | 43.88±12.32[ | 47.38±13.14[ |
| 200 mg/kg | 35.00±6.19[ | 38.00±11.16[ | 34.50±10.38[ | 36.38±10.25[ | 42.38±11.67[ |
| 400 mg/kg | 19.88±3.23[ | 28.13±12.56[ | 24.75±7.36[ | 27.88±10.37[ | 32.75±12.83[ |
Values are expressed as mean ± standard deviation (n=8).
P<0.01 vs. intact control
P<0.01 vs. UVB control
P<0.05 vs. intact control. UVB, ultraviolet B; PARP, cleaved poly(ADP-ribose) polymerase; NT, nitrotyrosine; 4-HNE, 4-Hydroxynonenal; MMP, matrix metalloproteinase; PCP, dried pomegranate juice concentrated powder; PCS, pomegranate juice concentrated solution.